Printer Friendly

ARGUS PHARMACEUTICALS POSTPONES PUBLIC OFFERING

 HOUSTON, March 15 /PRNewswire/ -- Argus Pharmaceuticals, Inc. (NASDAQ-NMS: ARGS) announced today that it has postponed its public offering of 2.5 million shares due to current market conditions for biomedical company stocks.
 The underwriters are S.G. Warburg Securities and Kidder, Peabody & Co. Incorporated.
 Argus Pharmaceuticals, Inc. designs and develops proprietary pharmaceuticals for the treatment of life-threatening infections and cancers. The company's product candidates are based on the understanding of the macrophage, a key disease-fighting cell of the blood and immune system. Argus benefits from more than a decade of research on macrophages and lipid carriers conducted by a team of scientists at The University of Texas M.D. Anderson Cancer Center.
 Argus common stock trades on the NASDAQ National Market System under the symbol ARGS.
 -0- 3/15/93
 /CONTACT: Kenneth M. Cohen, vice president, business affairs of Argus Pharmaceuticals, Inc., 713-367-1666; or Bryan Oakley of Edelman Public Relations, 713-623-2666, for Argus Pharmaceuticals/
 (ARGS)


CO: Argus Pharmaceuticals, Inc. ST: Texas IN: MTC SU: OFR

WB -- NY021 -- 5935 03/15/93 10:13 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 15, 1993
Words:174
Previous Article:HADSON ENERGY RESOURCES CORPORATION ANNOUNCES 1992 FINANCIAL RESULTS AND RESERVE ESTIMATES; PROFITABILITY RESTORES AFTER PRIOR YEAR SET-BACK
Next Article:WITCO PROMOTES SODERLIND TO SENIOR VICE PRESIDENT
Topics:


Related Articles
ARGUS PHARMACEUTICALS TO START HUMAN CLINICAL TRIALS ON POTENTIAL LEUKEMIA TREATMENT
ARGUS PHARMACEUTICALS BEGINS HUMAN CLINICAL TRIALS ON POTENTIAL LEUKEMIA TREATMENT
ARGUS PHARMACEUTICALS REPORTS ON SECOND QUARTER OPERATING RESULTS
ARGUS AND GENZYME SIGN AGREEMENT ON LEUKEMIA DRUG
ARGUS PHARMACEUTICALS, INC. FILES REGISTRATION STATEMENT
ARGUS PHARMACEUTICALS REPORTS ON THIRD QUARTER OPERATING RESULTS
ARGUS PHARMACEUTICALS COMPLETES SECONDARY PUBLIC OFFERING
ARGUS PHARMACEUTICALS OVER-ALLOTMENT EXERCISED ON SECONDARY PUBLIC OFFERING
ARGUS PHARMACEUTICALS EXPANDS ANTI-FUNGAL TRIALS
Relsys Awarded Contract by Genentech For Argus Safety(TM) Pharmacovigilance Software Solution.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters